BioSpace News Archive

Scepter Holdings, Inc., (OTC PINK:BRZL) a high-performance consumer goods sales and marketing company, is pleased to announce that Nosebudz® Nasal Air Filters are now available for purchase from Amazon.com.

Medical Pharmacies Group Limited is pleased to announce its partnership with Insig Corporation, the leading virtual care platform for physicians and other health care providers across Canada, to bring new virtual healthcare services to our clients.

Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal, Circuit Clinical will oversee the early clinical development of Intrommune’s lead drug, INT301, including a Phase 1b study planned for Q4 2020 and Q1 2021. “We are excited about the opportunity to partner with Circuit Clinical to support the development of peanut INT301,” said Michael Nelson, CEO

GigaGen Inc. , a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data detai

InstaShield, maker of the original ball-cap face shield, has been named one of the winners of the 19th annual Chicago Innovation Awards.

The Ad Council today announced new research findings regarding the current state of loneliness around the world.1

Immunicom, Inc. Founder and CEO, Amir Jafri, has been named one of the top eight healthcare leaders by CEO Today Magazine in its 2020 Healthcare Awards.

FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study.

Andrew Dreyfus, President and CEO of Blue Cross Blue Shield of Massachusetts , gave the following statement today during the Massachusetts Health Policy Commission’s Health Care Cost Trends Hearing, COVID-19 and the MA Health Care System: Assessing Impact, Advancing Equity:

Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m) Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019 Order backlog of €50.7m Cash and cash equivalents of €17.3m